Drug intelligence / Profile preview

beta 1,3-1,6 glucan

Development stage
Preclinical
Lead developer
GN Corporation
Administration
Oral
01

Overview

Beta 1,3-1,6 glucan is a naturally occurring polysaccharide derived from the cell wall of the black yeast *Aureobasidium pullulans*. Developed by Nichi Glucan and GN Corporation, it functions as an immunomodulatory adjuvant and biological response modifier. The compound is primarily utilized as a dietary supplement to support immune function in various conditions. Specifically, the **Neu-REFIX** formulation has received FDA Orphan Drug Designation and Rare Pediatric Disease Designation for the treatment of Duchenne Muscular Dystrophy (DMD), where it is investigated for its ability to modulate inflammation and potentially slow disease progression. The **Nichi Brite** formulation is used as a supportive adjuvant in patients with gastrointestinal and hepatobiliary cancers, including pancreatic and bile duct cancers. Its mechanism involves the activation of innate immune cells such as macrophages and natural killer (NK) cells.

Brand names
Neu-REFIXNichi Brite
Other names
Aureobasidium pullulans beta-glucanNichi Glucan
02

Targets

LacCer (Lactosylceramide)TLR2 (Toll-like Receptor 2)αMβ2 (Integrin αMβ2)CLEC7A (Dectin-1)CD36 (CD36 antigen)

Beyond the preview

Go deeper on beta 1,3-1,6 glucan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on beta 1,3-1,6 glucan.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call